Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK
204 Emerging evidence from a three-week trial in 22 chronic tinnitus patients without substantial hearing loss suggests a trans-tympanic device for stimulating the cochlea may help reduce tinnitus while preserving hearing, and represents a potential option for tinnitus sufferers without hearing loss

Examples include: peptide therapy (at high doses or long-term use) TB-500 (Thymosin Beta-4) VEGF-mimetic peptides Tesamorelin/peptide therapy (via IGF-1 pathways) Potential risks of prolonged use: Scar tissue overdevelopment Feeding abnormal or cancerous cell growth Disrupting blood flow in sensitive tissues (eyes, kidneys) Thats why we recommend cycles like: TB-500 : 610 weeks on, 4+ weeks off peptide therapy injections : short-term, with oral BPC for maintenance Tesamorelin/peptide therapy : rotated or paused to avoid overexposure Other Peptides That Benefit From Cycling Even non-angiogenic peptides benefit from breaks: Thymosin Alpha-1 : 5-week cycles, 23x per year GHK-Cu : 78 week cycles, followed by rest Semax & Dihexa : pulsed use to maintain brain sensitivity 5-Amino-1MQ : cycled after 23 rounds for metabolic reset Each protocol is tailored to half-life, tissue targets, and sensitivity feedback

What this means for you: the association keeps appearing across independent studies, which is why doctors take an unexplained elevation seriously